Loading patent…
AssigneeBiodesix, Inc.
InventorsCarlos Oliveira, Heinrich Roder, Joanna Roder
Estimating the term…
Laboratory test apparatus for conducting a mass spectrometry test on a blood-based sample of a cancer patient includes a classification procedure implemented in a programmed computer that generates a class label. In one form of the test, “Test 1”, if the sample is labelled “Bad” or equivalent the patient is predicted to exhibit primary immune resistance if they are later treated with anti-PD-1 or anti-PD-L1 therapies. In “Test 2” the Bad class label predicts that the patient will have a poor prognosis in response to treatment by either anti-PD-1 or anti-PD-L1 therapies or alternative chemotherapies, such as docetaxel or pemetrexed. “Test 3” identifies patients that are likely to have a poor prognosis in response to treatment by either anti-PD-1 or anti-PD-L1 therapies but have improved outcomes on alternative chemotherapies. A Good class label by either Test 1 or 2 predicts very good outcome on anti-PD-1 or anti-PD-L1 monotherapy.
Testing apparatus comprising, in combination:
A method of detecting a first and second class label in a cancer patient, comprising, in combination:
A method of detecting a class label in a non-small-cell lung cancer patient, comprising:
A testing apparatus comprising, in combination:
Dependencies are inferred from the claim text.